FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer

1. The U.S. Food and Drug Administration (FDA) has approved ImmunityBio's combination therapy for treating bladder cancer.
2. This innovative treatment combines two immunotherapy drugs, N-803 and BCG, to stimulate the immune system and fight cancer cells.
3. ImmunityBio's therapy has shown promising results in clinical trials, demonstrating improved efficacy and reduced side effects compared to traditional treatments.
4. Bladder cancer is the sixth most common cancer in the United States, with an estimated 81,400 new cases and 17,980 deaths in 2020.
5. The FDA's approval of ImmunityBio's combination therapy marks a significant milestone in the fight against bladder cancer, offering new hope for patients and their families.
6. ImmunityBio plans to continue researching and developing this therapy to further improve its effectiveness and expand its use to other types of cancer.